SEC Form 4Coverage since Jun 1, 2026
$DNTH insider trading
Over the last 12 months, Dianthus Therapeutics insiders reported no purchases and 6 sales totaling $25.9M across SEC Form 4 filings. 100% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $25.9M 6 events
- Events · 12m
- 6 Form 4 filings, grouped
- Insiders · 12m
- 4 distinct reporters
- 10b5-1 share
- 100% pre-arranged plans
Side
Price · $DNTH · 12Mvia TradingView
Top insiders · 12m
Randhawa SimratEVP, Head of R&D3× · $2.4M
Veness Adam MSVP, General Counsel and Sec.1× · $2.4M
Savitz RyanEVP, CFO & CBO1× · $3.2M
Garcia MarinoCEO AND PRESIDENT1× · $17.9M
All insider trades
6 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 7, 2026 | Garcia MarinoCEO AND PRESIDENT · O·D | ▼ Sale | 166,000 | $108.11 | $17.9M | -71.8% | plan · 7 tranches |
| Jul 9, 2026 | Savitz RyanEVP, CFO & CBO · O | ▼ Sale | 31,249 | $101.03 | $3.2M | -100% | plan · 3 tranches |
| Jun 17, 2026 | Veness Adam MSVP, General Counsel and Sec. · O | ▼ Sale | 30,000 | $80.8 | $2.4M | -100% | plan · 2 tranches |
| Jun 1, 2026 | Randhawa SimratEVP, Head of R&D · O | ▼ Sale | 4,159 | $91.37 | $380K | -51% | plan |
| Jun 1, 2026 | Randhawa SimratEVP, Head of R&D · O | ▼ Sale | 16,943 | $90.72 | $1.5M | -67.5% | plan |
| Jun 1, 2026 | Randhawa SimratEVP, Head of R&D · O | ▼ Sale | 5,428 | $89.72 | $487K | -17.8% | plan |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $DNTH feed.